A phase II clinical study investigating the efficacy of mesenchymal stem cells [MSCs] to treat moderate to severe lupus symptoms has been launched by the Lupus Foundation of America, in collaboration with the National Institute of Allergy and Infectious Diseases (part of the NIH). Lupus is a chronic autoimmune disorder in which the immune system can affect virtually any tissue in the body, including skin, joints and organs. MSCs represent a promising treatment option in that, in addition to the inherent plasticity of MSCs, they also possess immune modulation properties. The NIH is providing resources and oversight for the study, which will investigate how mesenchymal stem cells can effectively regulate and limit the autoimmune response of Lupus sufferers. Currently there are no effective options for their lupus symptoms other than steroid treatments, which have significant side effects, as they are detrimental to vital organ function.
This is an important development for lupus research, given that without proper funding and oversight many treatments never get off the ground, and life-saving cures could be delayed for years. “Robust funding is vital to moving lupus research forward. Without sufficient funding from public and private resources, research treatments will be delayed, and the search for better treatments and cures will be seriously impaired,” says Sandra Raymond, CEO of the Lupus Foundation of America.
As treatments emerge, we believe the best stem cells to use will be the patient’s own [autologous stem cells] as this negates the need to find a suitable donor and eliminates the chances of rejection of the transplanted tissue. To learn how to bank your own valuable stem cells to insure your future health, visit www.StemSave.com or call 877-783-6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.